Financhill
Sell
31

ILMN Quote, Financials, Valuation and Earnings

Last price:
$135.00
Seasonality move :
6.39%
Day range:
$133.50 - $135.69
52-week range:
$100.09 - $156.66
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
4.89x
P/B ratio:
10.07x
Volume:
677.7K
Avg. volume:
2.3M
1-year change:
-1.27%
Market cap:
$21.4B
Revenue:
$4.5B
EPS (TTM):
-$9.96

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
ILMN
Illumina
$1.1B $0.88 -4.48% 430.2% $148.36
CTSO
CytoSorbents
$10.2M -$0.06 28.63% -41.38% --
DCTH
Delcath Systems
$10.5M -$0.19 2204.21% -93.94% --
EXAS
Exact Sciences
$717M -$0.10 8.59% -18.18% $71.86
PGNY
Progyny
$297.4M $0.37 2.66% 183.52% $30.22
STRR
Star Equity Holdings
$13.2M -$0.32 21.89% -605.27% --
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
ILMN
Illumina
$134.96 $148.36 $21.4B -- $0.00 0% 4.89x
CTSO
CytoSorbents
$0.90 -- $49.5M -- $0.00 0% 1.40x
DCTH
Delcath Systems
$11.97 -- $382.7M -- $0.00 0% 14.35x
EXAS
Exact Sciences
$57.48 $71.86 $10.6B -- $0.00 0% 3.91x
PGNY
Progyny
$14.71 $30.22 $1.3B 25.36x $0.00 0% 1.27x
STRR
Star Equity Holdings
$2.18 -- $7M 0.70x $0.00 0% 0.14x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
ILMN
Illumina
48.34% 0.395 9.65% 1.68x
CTSO
CytoSorbents
51.51% 0.791 16.8% 1.46x
DCTH
Delcath Systems
18.92% 0.853 0.79% 0.97x
EXAS
Exact Sciences
44.45% -0.061 20.38% 1.78x
PGNY
Progyny
-- 1.563 -- 2.48x
STRR
Star Equity Holdings
15.99% -0.852 31.89% 1.35x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
ILMN
Illumina
$745M $253M -26.73% -37.83% 70% $284M
CTSO
CytoSorbents
$4.5M -$4.4M -70.49% -103.21% -20.27% -$2.8M
DCTH
Delcath Systems
$9.6M -$1.3M -167.55% -251.36% -11.24% -$3.9M
EXAS
Exact Sciences
$512.6M -$20.8M -3.82% -6.77% -4.11% $112.6M
PGNY
Progyny
$59.2M $12.5M 11.31% 11.31% 4.35% $42.7M
STRR
Star Equity Holdings
$2.8M -$5.3M -9.23% -10.13% -38.95% $420K

Illumina vs. Competitors

  • Which has Higher Returns ILMN or CTSO?

    CytoSorbents has a net margin of 65.28% compared to Illumina's net margin of -27.1%. Illumina's return on equity of -37.83% beat CytoSorbents's return on equity of -103.21%.

    Company Gross Margin Earnings Per Share Invested Capital
    ILMN
    Illumina
    68.98% $4.42 $4.1B
    CTSO
    CytoSorbents
    52.3% -$0.04 $26.8M
  • What do Analysts Say About ILMN or CTSO?

    Illumina has a consensus price target of $148.36, signalling upside risk potential of 21.16%. On the other hand CytoSorbents has an analysts' consensus of -- which suggests that it could grow by 455.56%. Given that CytoSorbents has higher upside potential than Illumina, analysts believe CytoSorbents is more attractive than Illumina.

    Company Buy Ratings Hold Ratings Sell Ratings
    ILMN
    Illumina
    9 10 0
    CTSO
    CytoSorbents
    0 0 0
  • Is ILMN or CTSO More Risky?

    Illumina has a beta of 1.105, which suggesting that the stock is 10.544% more volatile than S&P 500. In comparison CytoSorbents has a beta of 0.568, suggesting its less volatile than the S&P 500 by 43.192%.

  • Which is a Better Dividend Stock ILMN or CTSO?

    Illumina has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CytoSorbents offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Illumina pays -- of its earnings as a dividend. CytoSorbents pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ILMN or CTSO?

    Illumina quarterly revenues are $1.1B, which are larger than CytoSorbents quarterly revenues of $8.6M. Illumina's net income of $705M is higher than CytoSorbents's net income of -$2.3M. Notably, Illumina's price-to-earnings ratio is -- while CytoSorbents's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Illumina is 4.89x versus 1.40x for CytoSorbents. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ILMN
    Illumina
    4.89x -- $1.1B $705M
    CTSO
    CytoSorbents
    1.40x -- $8.6M -$2.3M
  • Which has Higher Returns ILMN or DCTH?

    Delcath Systems has a net margin of 65.28% compared to Illumina's net margin of 16.64%. Illumina's return on equity of -37.83% beat Delcath Systems's return on equity of -251.36%.

    Company Gross Margin Earnings Per Share Invested Capital
    ILMN
    Illumina
    68.98% $4.42 $4.1B
    DCTH
    Delcath Systems
    85.36% $0.06 $10.6M
  • What do Analysts Say About ILMN or DCTH?

    Illumina has a consensus price target of $148.36, signalling upside risk potential of 21.16%. On the other hand Delcath Systems has an analysts' consensus of -- which suggests that it could grow by 78.22%. Given that Delcath Systems has higher upside potential than Illumina, analysts believe Delcath Systems is more attractive than Illumina.

    Company Buy Ratings Hold Ratings Sell Ratings
    ILMN
    Illumina
    9 10 0
    DCTH
    Delcath Systems
    0 0 0
  • Is ILMN or DCTH More Risky?

    Illumina has a beta of 1.105, which suggesting that the stock is 10.544% more volatile than S&P 500. In comparison Delcath Systems has a beta of 0.851, suggesting its less volatile than the S&P 500 by 14.882%.

  • Which is a Better Dividend Stock ILMN or DCTH?

    Illumina has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Delcath Systems offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Illumina pays -- of its earnings as a dividend. Delcath Systems pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ILMN or DCTH?

    Illumina quarterly revenues are $1.1B, which are larger than Delcath Systems quarterly revenues of $11.2M. Illumina's net income of $705M is higher than Delcath Systems's net income of $1.9M. Notably, Illumina's price-to-earnings ratio is -- while Delcath Systems's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Illumina is 4.89x versus 14.35x for Delcath Systems. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ILMN
    Illumina
    4.89x -- $1.1B $705M
    DCTH
    Delcath Systems
    14.35x -- $11.2M $1.9M
  • Which has Higher Returns ILMN or EXAS?

    Exact Sciences has a net margin of 65.28% compared to Illumina's net margin of -5.4%. Illumina's return on equity of -37.83% beat Exact Sciences's return on equity of -6.77%.

    Company Gross Margin Earnings Per Share Invested Capital
    ILMN
    Illumina
    68.98% $4.42 $4.1B
    EXAS
    Exact Sciences
    72.33% -$0.21 $5.8B
  • What do Analysts Say About ILMN or EXAS?

    Illumina has a consensus price target of $148.36, signalling upside risk potential of 21.16%. On the other hand Exact Sciences has an analysts' consensus of $71.86 which suggests that it could grow by 25.01%. Given that Exact Sciences has higher upside potential than Illumina, analysts believe Exact Sciences is more attractive than Illumina.

    Company Buy Ratings Hold Ratings Sell Ratings
    ILMN
    Illumina
    9 10 0
    EXAS
    Exact Sciences
    17 3 0
  • Is ILMN or EXAS More Risky?

    Illumina has a beta of 1.105, which suggesting that the stock is 10.544% more volatile than S&P 500. In comparison Exact Sciences has a beta of 1.237, suggesting its more volatile than the S&P 500 by 23.719%.

  • Which is a Better Dividend Stock ILMN or EXAS?

    Illumina has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Exact Sciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Illumina pays -- of its earnings as a dividend. Exact Sciences pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ILMN or EXAS?

    Illumina quarterly revenues are $1.1B, which are larger than Exact Sciences quarterly revenues of $708.7M. Illumina's net income of $705M is higher than Exact Sciences's net income of -$38.2M. Notably, Illumina's price-to-earnings ratio is -- while Exact Sciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Illumina is 4.89x versus 3.91x for Exact Sciences. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ILMN
    Illumina
    4.89x -- $1.1B $705M
    EXAS
    Exact Sciences
    3.91x -- $708.7M -$38.2M
  • Which has Higher Returns ILMN or PGNY?

    Progyny has a net margin of 65.28% compared to Illumina's net margin of 3.64%. Illumina's return on equity of -37.83% beat Progyny's return on equity of 11.31%.

    Company Gross Margin Earnings Per Share Invested Capital
    ILMN
    Illumina
    68.98% $4.42 $4.1B
    PGNY
    Progyny
    20.67% $0.11 $434.9M
  • What do Analysts Say About ILMN or PGNY?

    Illumina has a consensus price target of $148.36, signalling upside risk potential of 21.16%. On the other hand Progyny has an analysts' consensus of $30.22 which suggests that it could grow by 28.19%. Given that Progyny has higher upside potential than Illumina, analysts believe Progyny is more attractive than Illumina.

    Company Buy Ratings Hold Ratings Sell Ratings
    ILMN
    Illumina
    9 10 0
    PGNY
    Progyny
    4 4 0
  • Is ILMN or PGNY More Risky?

    Illumina has a beta of 1.105, which suggesting that the stock is 10.544% more volatile than S&P 500. In comparison Progyny has a beta of 1.350, suggesting its more volatile than the S&P 500 by 34.952%.

  • Which is a Better Dividend Stock ILMN or PGNY?

    Illumina has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Progyny offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Illumina pays -- of its earnings as a dividend. Progyny pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ILMN or PGNY?

    Illumina quarterly revenues are $1.1B, which are larger than Progyny quarterly revenues of $286.6M. Illumina's net income of $705M is higher than Progyny's net income of $10.4M. Notably, Illumina's price-to-earnings ratio is -- while Progyny's PE ratio is 25.36x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Illumina is 4.89x versus 1.27x for Progyny. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ILMN
    Illumina
    4.89x -- $1.1B $705M
    PGNY
    Progyny
    1.27x 25.36x $286.6M $10.4M
  • Which has Higher Returns ILMN or STRR?

    Star Equity Holdings has a net margin of 65.28% compared to Illumina's net margin of -14.42%. Illumina's return on equity of -37.83% beat Star Equity Holdings's return on equity of -10.13%.

    Company Gross Margin Earnings Per Share Invested Capital
    ILMN
    Illumina
    68.98% $4.42 $4.1B
    STRR
    Star Equity Holdings
    20.62% -$0.78 $69.5M
  • What do Analysts Say About ILMN or STRR?

    Illumina has a consensus price target of $148.36, signalling upside risk potential of 21.16%. On the other hand Star Equity Holdings has an analysts' consensus of -- which suggests that it could grow by 358.72%. Given that Star Equity Holdings has higher upside potential than Illumina, analysts believe Star Equity Holdings is more attractive than Illumina.

    Company Buy Ratings Hold Ratings Sell Ratings
    ILMN
    Illumina
    9 10 0
    STRR
    Star Equity Holdings
    0 0 0
  • Is ILMN or STRR More Risky?

    Illumina has a beta of 1.105, which suggesting that the stock is 10.544% more volatile than S&P 500. In comparison Star Equity Holdings has a beta of 0.080, suggesting its less volatile than the S&P 500 by 91.951%.

  • Which is a Better Dividend Stock ILMN or STRR?

    Illumina has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Star Equity Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Illumina pays -- of its earnings as a dividend. Star Equity Holdings pays out 7.62% of its earnings as a dividend. Star Equity Holdings's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios ILMN or STRR?

    Illumina quarterly revenues are $1.1B, which are larger than Star Equity Holdings quarterly revenues of $13.7M. Illumina's net income of $705M is higher than Star Equity Holdings's net income of -$2M. Notably, Illumina's price-to-earnings ratio is -- while Star Equity Holdings's PE ratio is 0.70x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Illumina is 4.89x versus 0.14x for Star Equity Holdings. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ILMN
    Illumina
    4.89x -- $1.1B $705M
    STRR
    Star Equity Holdings
    0.14x 0.70x $13.7M -$2M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

How High Will Airbnb Stock Go?
How High Will Airbnb Stock Go?

Airbnb, Inc. (NASDAQ:ABNB) share price has seen substantial turbulence over…

Why Is SoundHound AI Stock Up So Much?
Why Is SoundHound AI Stock Up So Much?

Like many companies improving AI technologies and exploring ways to…

Is The Santa Claus Rally The Gift That Keeps Giving?
Is The Santa Claus Rally The Gift That Keeps Giving?

Remember the horror of 2008 when the Great Recession hit…

Stock Ideas

Buy
65
Is AAPL Stock a Buy?

Market Cap: $3.9T
P/E Ratio: 43x

Buy
56
Is NVDA Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 117x

Buy
57
Is MSFT Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 37x

Alerts

Buy
64
ARQQ alert for Dec 27

Arqit Quantum [ARQQ] is up 49.85% over the past day.

Buy
64
QMCO alert for Dec 27

Quantum [QMCO] is up 49.62% over the past day.

Buy
65
ALGS alert for Dec 27

Aligos Therapeutics [ALGS] is up 10.88% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock